Anisha Nagpal

Anisha Nagpal

Auto-generated profile, based on publicly available information

Anisha Nagpal

Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Psychoneuroendocrinology
Verified
Journal Article
Open access
ANAnisha Nagpal
Anisha Nagpal
KSKatja Schmalenberger
Katja Schmalenberger
JBJordan C. Barone
Jordan C. Barone
EMElizabeth Mulligan
Elizabeth Mulligan
ASAllison Stumper
Allison Stumper
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
Despite decades of research, there is no scientific consensus method for representing the menstrual cycle as a continuous timeline. Common phase- and count-based methods oversimplify hormonal dynamics and overlook individual variability in ovulation timing, reducing statistical power and misaligning trajectories. To address this, we introduce Phase-Aligned Cycle Time Scaling (PACTS) and its companion R package, `menstrualcycleR`, which generates continuous time variables anchored to both menses and ovulation, improving alignment of hormonal dynamics across individuals and cycles in an accessible, reproducible way. This approach accommodates variable cycle lengths and supports various ovulation detection methods or norm-based ovulation estimation when biomarkers are unavailable. Using daily urinary hormone data from 44 cycles, we show that PACTS improves alignment and estimation of estradiol (E2) and progesterone (P4) trajectories compared to traditional methods. This has implications for improved cycle effect estimation both within samples and across studies. The variables produced by PACTS also support hierarchical nonlinear models, such as generalized additive mixed models, for high-resolution analysis of cyclical outcomes and quantification of related effect sizes. Since a variety of clinical disorders are currently diagnosed using cycle count methods, future directions should consider how this approach may improve diagnostic accuracy (e.g., in premenstrual dysphoric disorder (PMDD), catamenial epilepsy, or menstrual migraine). Together, PACTS and `menstrualcycleR` offer a reproducible framework that improves precision and interpretability in menstrual cycle research.

14 October 2024 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
ANAnisha Nagpal
Anisha Nagpal
JBJordan C. Barone
Jordan C. Barone
HTHafsah Tauseef
Hafsah Tauseef
JRJaclyn Ross
Jaclyn Ross
ZGZach J. Gray
Zach J. Gray
TETory Eisenlohr-Moul
Tory Eisenlohr-Moul
Background: Affective responses to the menstrual cycle vary widely. Some individuals experience severe symptoms like those with premenstrual dysphoric disorder, while others have minimal changes. The reasons for these differences are unclear, but prior studies suggest stressor exposure may play a role. However, research in at-risk psychiatric samples is lacking.Methods: In a large clinical sample, we conducted a prospective study of how lifetime stressors relate to degree of affective change across the cycle. 114 outpatients with past-month suicidal ideation (SI) provided daily ratings (n = 6187) of negative affect and SI across 1–3 menstrual cycles. Participants completed the Stress and Adversity Inventory (STRAIN), which measures different stressor exposures (i.e. interpersonal loss, physical danger) throughout the life course, including before and after menarche. Multilevel polynomial growth models tested the relationship between menstrual cycle time and symptoms, moderated by stressor exposure.Results: Greater lifetime stressor exposure predicted a more pronounced perimenstrual increase in active SI, along with marginally significant similar patterns for negative affect and passive SI. Additionally, pre-menarche stressors significantly increased the cyclicity of active SI compared to post-menarche stressors. Exposure to more interpersonal loss stressors predicted greater perimenstrual symptom change of negative affect, passive SI and active SI. Exploratory item-level analyses showed that lifetime stressors moderated a more severe perimenstrual symptom trajectory for mood swings, anger/irritability, rejection sensitivity, and interpersonal conflict.Conclusion: These findings suggest that greater lifetime stressor exposure may lead to heightened emotional reactivity to ovarian hormone fluctuations, elevating the risk of psychopathology.

10 September 2024 in Psychiatry Research
Verified
Journal Article
Open access
KSKatja Schmalenberger
Katja Schmalenberger
EMElizabeth M. Mulligan
Elizabeth M. Mulligan
JBJordan C. Barone
Jordan C. Barone
ANAnisha Nagpal
Anisha Nagpal
MDMadeline M. Divine
Madeline M. Divine
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
Accumulating evidence indicates that most female patients with suicidal ideation (SI) experience a dimensional worsening of depressive symptoms and SI in the perimenstrual phase of the menstrual cycle. Experimental trials demonstrate that acute perimenstrual administration of estradiol (E2; with or without progesterone/P4), can prevent these recurring episodes of increased risk. In this archival sample drawn from one of these clinical trials, we examined whether these beneficial E2 effects extend to specific types of cognition. For a double-blind, placebo-controlled experiment, we recruited transdiagnostic psychiatric outpatients with natural menstrual cycles who experienced past-month SI (N(per-protocol sample)=23; N(intent-to-treat sample)=44). In each of two counterbalanced conditions (perimenstrual administration of 0.1mg/d transdermal E2 vs. placebo), participants completed three cognitive tasks in three menstrual cycle phases (mid-luteal, perimenstrual, mid-follicular). Multilevel models revealed a significant interaction of condition and phase: E2 administration prevented mid-luteal-to-perimenstrual drops in working memory (p=.006) and verbal fluency (p=.005) observed under placebo. No effects were found for inhibitory control. In conclusion, we find perimenstrual declines in working memory and verbal fluency in patients with SI, which can be prevented by administering E2. This study contributes to our understanding of the hormone-brain pathways involved in the cyclical worsening of suicidality.

6 December 2023 in OSF Preprints
Verified
Preprint
Open access
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
JBJordan Barone
Jordan Barone
GPGraziano Pinna
Graziano Pinna
MWMelissa Wagner-Schuman
Melissa Wagner-Schuman
FAFelipe B. Almeida
Felipe B. Almeida
SGSusan Girdler
Susan Girdler
Background: Across several patient cohorts recruited for recent suicidal ideation (SI), current affective disorder, and natural menstrual cycles, we have observed a dimensional (present to varying degrees) perimenstrual (PM) worsening of SI and depressed mood, specifically relative to an early luteal (EL) nadir. In our prior crossover trial, PM administration of combined estradiol (E2) and progesterone (P4) reduced this exacerbation of SI and depressive symptoms versus placebo (PBO). This three-period crossover trial extended this work by examining independent effects of E2, P4, and PBO on PM worsening of SI and related depressive symptoms. Further, we examined two neuroactive steroid metabolites of P4 (3α,5α-tetrahydroxyprogesterone or allopregnanolone/ALLO, 3α,5β-tetrahydroxyprogesterone or pregnanolone/PA), since some have hypothesized that NAS withdrawal contributes to PM affective changes.Methods: A naturally-cycling transdiagnostic sample with affective disorder and past-month SI (N(per-protocol)=23; N(intent-to-treat)=44) completed three double-blind, counterbalanced conditions: perimenstrual administration of (1) .1mg/day transdermal E2 (plus PBO pills), (2) 200mg/day oral micronized P4 (plus PBO patch), and (3) PBO patch and pills. From three visits per condition (+7, +14, and +22 days after an LH surge of >= 40 mIU/ml), blood was assayed (via GC/MS) for E2, P4, ALLO, and PA. Results: Despite the fact that only P4 (vs. PBO) prevented PM withdrawal of ALLO and PA, P4 (vs. PBO) increased PM worsening of SI, but had no other symptom effects. In contrast, E2 (vs. PBO) reduced PM worsening of SI, depressed mood, hopelessness, anxiety, overwhelm, rejection sensitivity, and perceived burdensomeness—even though it did not prevent ALLO or PA withdrawal. Conclusions: Cyclical worsening of depressive symptoms and SI are improved with perimenstrual E2 administration, implicating E2 withdrawal or depletion as a mechanism. Cyclical withdrawal or depletion from P4, ALLO, or PA may not contribute to cyclical affective changes, and P4 administration may worsen SI.

20 December 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JBJordan C. Barone
Jordan C. Barone
RRRaffaele Romano
Raffaele Romano
ANAnisha Nagpal
Anisha Nagpal
ASAntonio Salerno
Antonio Salerno
APAnna Patterson
Anna Patterson
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
Menstrual cycle affective change (MCAC), including conditions like Premenstrual Dysphoric Disorder (PMDD), is triggered by ovarian hormone fluctuations, but its neurobiological mechanisms remain poorly understood. A leading hypothesis implicates abnormal GABA-A receptor (GABAAR) subunit regulation in altering sensitivity to neuroactive steroids, a theory difficult to test in humans. We examined peripheral mRNA expression of GABRD, GABRG2, and GABRA5 in a transdiagnostic sample of 112 participants (75 psychiatric outpatients with suicidality; 37 controls) to capture a dimensional range of MCAC severity. Participants provided daily affect ratings and five LH-timed blood samples using PAXgene tubes for RT-PCR analysis. Replicating preclinical findings, GABRG2 expression decreased during the midluteal phase. Critically, individual differences in both person-mean expression and perimenstrual change (AUCi) were correlated with cyclical symptom trajectories. Greater perimenstrual increases or higher average expression were associated with classic luteal-phase worsening of anxiety (GABRG2, GABRA5), irritability (GABRG2), and suicidal ideation (GABRG2, GABRA5, GABRD). However, relative to those with moderate or stable expression, perimenstrual decreases or lower average expression were also linked to cyclical worsening of anxiety and suicidal ideation that emerged around menses and persisted into the follicular phase. Overall, more stable subunit expression was associated with less cyclical symptom change. These findings could be consistent with a loss of homeostatic stability in GABAergic plasticity, rather than a simple unidirectional differences in levels or changes, as a potential correlate of MCAC. Peripheral GABAAR gene expression warrants further investigation, particularly in experimental studies, to determine whether there are causal associations between subunit gene expression and MCAC.

16 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LKLoran Knol
Loran Knol
MRMindy K Ross
Mindy K Ross
ANAnisha Nagpal
Anisha Nagpal
ABAndrew P. Burns
Andrew P. Burns
ZMZachery D. Morrissey
Zachery D. Morrissey
AMAndre F. Marquand
Andre F. Marquand
Diurnal rhythms are an integral feature of psychopathology but difficult to measure at scale. Smartphones are ubiquitous and therefore uniquely positioned to measure such rhythms non-invasively and continuously. Here, we propose a digital phenotyping framework to quantify diurnal rhythms. We use it to predict sleep duration from smartphone typing dynamics and analyse rhythm phase during time zone transitions with a clinical outpatient sample and a year-long longitudinal data set.